Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Lilly shares slip as FDA seeks more Alzheimer's drug data

Eli Lilly shares slipped Friday morning after regulators said they need to see more data on the company’s application for a quick approval of its potential Alzheimer’s disease treatment

The Associated Press
Friday 20 January 2023 14:17 GMT
Eli Lilly-Potential Alzheimer's Drug
Eli Lilly-Potential Alzheimer's Drug (Copyright 2017 The Associated Press. All rights reserved.)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Eli Lilly shares slipped Friday morning after regulators said they need to see more data on the company’s application for a quick approval of its potential Alzheimer’s disease treatment.

Lilly said the Food and Drug Administration wants information from at least 100 patients who received a minimum of 12 months of continued treatment on donanemab. The drugmaker gave the update after markets closed Thursday.

The potential treatment aims to clear a plaque from the brain that is a key hallmark of the mind-robbing disease.

Lilly said it had more than 100 patients in the study used for its accelerated approval application. But many were able to stop taking the drug as early as 6 months into treatment due to the reduction in plaque.

The FDA’s accelerated approval program allows drugs to launch in the U.S. based on promising early results, before they’re a confirmed benefit to patients. The agency granted accelerated approval earlier this month to another Alzheimer’s drug, Leqembi from Japan’s Eisai.

Lilly is still seeking full approval for its drug. The company expects to report early results from a late-stage study in the second quarter.

SVB Securities analyst David Risinger called the accelerated approval delay “immaterial.” He said in a research note that the drug’s sales prospects depend more on the late-stage study the drugmaker is wrapping up.

Shares of Indianapolis-based Eli Lilly and Co. slipped by about $5, or 1%, to $346 before markets opened Friday.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in